Sarepta Total Liab from 2010 to 2024
| SRPT Stock | USD 119.98 1.40 1.15% |
Total Liabilities | First Reported 1996-12-31 | Previous Quarter 2.4 B | Current Value 2.3 B | Quarterly Volatility 813.6 M |
Check Sarepta Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sarepta Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 61.8 M, Interest Expense of 23.1 M or Selling General Administrative of 506 M, as well as many indicators such as Price To Sales Ratio of 6.81, Dividend Yield of 0.0 or PTB Ratio of 6.7. Sarepta financial statements analysis is a perfect complement when working with Sarepta Therapeutics Valuation or Volatility modules.
Sarepta | Total Liab |
Latest Sarepta Therapeutics' Total Liab Growth Pattern
Below is the plot of the Total Liab of Sarepta Therapeutics over the last few years. It is the total amount of all liabilities that a company has, including both short-term and long-term liabilities. Sarepta Therapeutics' Total Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sarepta Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Total Liab | 10 Years Trend |
|
Total Liab |
| Timeline |
Sarepta Total Liab Regression Statistics
| Arithmetic Mean | 974,522,063 | |
| Geometric Mean | 227,631,835 | |
| Coefficient Of Variation | 113.04 | |
| Mean Deviation | 969,944,343 | |
| Median | 518,747,000 | |
| Standard Deviation | 1,101,631,008 | |
| Sample Variance | 1213590.9T | |
| Range | 2.7B | |
| R-Value | 0.91 | |
| Mean Square Error | 220981.5T | |
| R-Squared | 0.83 | |
| Slope | 224,543,284 | |
| Total Sum of Squares | 16990272.3T |
Sarepta Total Liab History
About Sarepta Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Sarepta Therapeutics income statement, its balance sheet, and the statement of cash flows. Sarepta Therapeutics investors use historical funamental indicators, such as Sarepta Therapeutics's Total Liab, to determine how well the company is positioned to perform in the future. Although Sarepta Therapeutics investors may use each financial statement separately, they are all related. The changes in Sarepta Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Sarepta Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Sarepta Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Sarepta Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Liabilities | 2.4 B | 2.5 B |
Pair Trading with Sarepta Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sarepta Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sarepta Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Sarepta Stock
The ability to find closely correlated positions to Sarepta Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sarepta Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sarepta Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sarepta Therapeutics to buy it.
The correlation of Sarepta Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sarepta Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sarepta Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sarepta Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Sarepta Stock Analysis
When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.